Modification of escalated beacopp with dacarbazine / procarbazine substitution reduces red cell transfusion requirements and may shorten time to menstrual period recovery
Jones, Steve
Jones, Steve
Abstract
It is increasingly common practice to modify escalated BEACOPP (eBPP) by removing oral procarbazine and replacing with intravenous dacarbazine (250mg/m2 D2‐3), hoping to reduce haematopoietic stem cell and gonadal toxicity. However, published data on the so‐called ‘escalated BEACOPDac (eBPDac)’ regimen are limited.
MIDER Authors
Citations
Altmetric:
Date
2019-06
Type
Article
Subject
Hodgkin Disease, eBPDac Therapy, Procarbazine
Collections
Citation
Follows, G. et al. (2019) ‘Modification of Escalated Beacopp with Dacarbazine / Procarbazine Substitution Reduces Red Cell Transfusion Requirements and May Shorten Time to Menstrual Period Recovery’, Hematological Oncology, 37, pp. 490–491. doi: 10.1002/hon.168_2631.
Journal / Source Title
DOI
PMID
Publisher
Publisher’s URL
Publisher’s statement
Available on publishers website.
https://onlinelibrary.wiley.com/doi/full/10.1002/hon.168_2631